poisar

Stock

Taysha Gene Therapies, Inc. TSHA

$6.01+0.00%

Overview

TSHA market data

Price History

TSHA price chart · 1M
O
5.95
H
6.09
L
5.90
C
6.01
Vol
65,277.00
Source
US equities market feed
Observed
Aug 27, 2026, 12:00 AM
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & Performance

Open
$5.95
Previous Close
$6.01
Day High
$6.09
Day Low
$5.90
52 Week High
$7.30
52 Week Low
$5.17
7 Day Return
-1.56%
30 Day Return
+10.28%
90 Day Return
+2.74%
1 Year Return
-4.30%
Daily Notional Volume
$392.3K
Latest daily bar volume multiplied by its closing price.

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$0.34
Diluted earnings per share over the trailing twelve months.
Beta
1.23
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-780.3%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$2.71 – $7.30
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $1.9B · P/B 6.10 · P/S 199.21.

Company News

10 captured
Taysha Gene Therapies shares are trading lower after the company reported worse-than-expected Q2 EPS results.Benzinga · Aug 12, 2026, 12:01 PM
Taysha Gene Therapies Q2 EPS $(0.13) Misses $(0.12) EstimateBenzinga · Aug 11, 2026, 8:00 PM
Taysha Gene Therapies Announces Commercial Supply Agreement With Catalent For Rett Syndrome Gene Therapy TSHA-102 Ahead Of Potential FDA ApprovalBenzinga · Aug 3, 2026, 12:01 PM
Goldman Sachs Maintains Buy on Taysha Gene Therapies, Raises Price Target to $13Benzinga · Jul 21, 2026, 12:43 PM
Taysha Gene Therapies shares are trading lower after a Form 4 filing showed its President and Head of R&D sold 200,000 shares at an average price of $6.24 each.Benzinga · Jul 13, 2026, 2:24 PM
Citizens Reiterates Market Outperform on Taysha Gene Therapies, Maintains $11 Price TargetBenzinga · Jul 2, 2026, 1:00 PM
Darden Restaurants To Rally Around 19%? Here Are 10 Top Analyst Forecasts For TuesdayBenzinga · Jun 30, 2026, 1:10 PM
Baird Maintains Outperform on Taysha Gene Therapies, Raises Price Target to $15Benzinga · Jun 30, 2026, 11:55 AM
8-K filing — Taysha Gene Therapies, Inc. (TSHA)SEC EDGAR · Jun 25, 2026, 8:26 PM
H.B. Fuller, Trip.com, Hertz Global And Other Big Stocks Moving Lower In Thursday Pre-Market SessionBenzinga · Jun 25, 2026, 12:15 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock